Chemours (NYSE:CC) Price Target Raised to $21.00 at Mizuho

Chemours (NYSE:CC) had its price objective increased by Mizuho from $17.00 to $21.00 in a research report sent to investors on Thursday morning,Benzinga reports. Mizuho currently has an outperform rating on the specialty chemicals company’s stock.

Several other brokerages also recently commented on CC. UBS Group increased their price objective on shares of Chemours from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a report on Wednesday, January 21st. Jefferies Financial Group restated a “hold” rating and issued a $17.00 price objective on shares of Chemours in a report on Monday, February 23rd. The Goldman Sachs Group increased their target price on Chemours from $14.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, JPMorgan Chase & Co. boosted their price target on Chemours from $13.00 to $17.00 and gave the stock a “neutral” rating in a research note on Monday, February 23rd. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Chemours has a consensus rating of “Hold” and a consensus price target of $18.40.

Chemours Stock Performance

Chemours stock opened at $16.70 on Thursday. Chemours has a twelve month low of $9.13 and a twelve month high of $21.85. The company has a quick ratio of 0.85, a current ratio of 1.78 and a debt-to-equity ratio of 16.33. The company has a market capitalization of $2.51 billion, a P/E ratio of -6.73 and a beta of 1.60. The stock’s 50 day moving average is $16.29 and its 200 day moving average is $14.73.

Chemours (NYSE:CC) last released its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The business had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the previous year, the company posted $0.09 earnings per share. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. On average, equities research analysts predict that Chemours will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Friday, February 27th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, February 27th. Chemours’s dividend payout ratio (DPR) is currently -14.11%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Chemours by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock worth $211,287,000 after acquiring an additional 490,778 shares in the last quarter. State Street Corp boosted its position in shares of Chemours by 22.7% in the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock worth $70,009,000 after purchasing an additional 1,131,682 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Chemours by 13.8% in the third quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock worth $75,971,000 after purchasing an additional 580,089 shares in the last quarter. UBS Group AG raised its position in shares of Chemours by 0.3% during the 3rd quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock valued at $75,311,000 after purchasing an additional 14,865 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Chemours during the 3rd quarter valued at $63,103,000. Institutional investors own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.